TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD
In plain words A Phase 1 and 2 study of TB-500 in people 40 to 75, run by Hudson Biotech. It plans to enroll about 80 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 40 to 75. Conditions: Atherosclerotic Cardiovascular Diseases; Endothelial Dysfunction.
- Age 40-75 years, able to provide written informed consent.
- Documented stable ASCVD (e.g., prior myocardial infarction >6 months ago, prior coronary revascularization, stable angina with objective evidence of ischemia, or symptomatic peripheral artery disease).
- On stable guideline-directed medical therapy (e.g., statin and antiplatelet therapy unless contraindicated) for at least 8 weeks before screening.
- Resting systolic blood pressure <160 mmHg and diastolic blood pressure <100 mmHg (with or without therapy).
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
TB-500; Placebo
Registered summary
This fictional study is an example of a ClinicalTrials.gov-style record. It describes a Phase 1/2 trial evaluating the safety and tolerability of TB-500 (a 17-23 fragment of thymosin beta 4) versus placebo in adults with stable atherosclerotic cardiovascular disease (ASCVD). Exploratory endpoints assess vascular function and inflammation biomarkers
Where, as registered
No US site; China (1).